Characterization of HIV-1-specific T-helper cells in acute and chronic infection
- PMID: 10203039
- DOI: 10.1016/s0165-2478(98)00165-5
Characterization of HIV-1-specific T-helper cells in acute and chronic infection
Abstract
HIV-1 infection is associated with progressive and relentless destruction of the immune system in the majority of infected persons, but some persons appear to be able to successfully contain the virus in the absence of antiviral therapy. Such cases suggest that the host immune response can successfully contain the virus, and provide the rationale for concerted efforts to understand the host immune response to the virus and to develop new strategies to combat the infection with immune based therapies. Historically, the greatest hole in the immune repertoire in HIV-1 infection has been the lack of strong virus-specific proliferative responses. However, new studies have identified a potent Th cell response in some infected persons, and have shown a statistically significant negative correlation between plasma viremia and virus-specific CD4 T-helper cells directed at the p24 protein. Moreover, early institution of potent antiviral therapy in the earliest stages of acute HIV-1 infection have led to persistent, strong HIV-1-specific T-helper cell responses, analogous to those seen in persons who are able to control viremia in the absence of antiviral therapy. We hypothesize that this is because potent antiviral therapy is able to protect virus-specific Th cells as they become activated, and thus these cells are not lost in the earliest stages of infection.
Similar articles
-
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.Science. 1997 Nov 21;278(5342):1447-50. doi: 10.1126/science.278.5342.1447. Science. 1997. PMID: 9367954
-
Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.J Virol. 1999 Aug;73(8):6715-20. doi: 10.1128/JVI.73.8.6715-6720.1999. J Virol. 1999. PMID: 10400769 Free PMC article.
-
Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.J Immunol. 2003 Dec 15;171(12):6968-75. doi: 10.4049/jimmunol.171.12.6968. J Immunol. 2003. PMID: 14662905
-
Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection.Clin Infect Dis. 2001 Jun 15;32(12):1756-68. doi: 10.1086/320759. Epub 2001 May 16. Clin Infect Dis. 2001. PMID: 11360218 Review.
-
Cellular immune response to human immunodeficiency virus.AIDS. 2001 Feb;15 Suppl 2:S16-21. doi: 10.1097/00002030-200102002-00004. AIDS. 2001. PMID: 11424972 Review.
Cited by
-
Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatment.Philos Trans R Soc Lond B Biol Sci. 2000 Aug 29;355(1400):1059-70. doi: 10.1098/rstb.2000.0643. Philos Trans R Soc Lond B Biol Sci. 2000. PMID: 11186307 Free PMC article. Review.
-
Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses.J Virol. 2000 Aug;74(15):6984-91. doi: 10.1128/jvi.74.15.6984-6991.2000. J Virol. 2000. PMID: 10888637 Free PMC article. Clinical Trial.
-
Hepatitis B virus (HBV)-specific T-cell responses to recombinant HBV core protein in patients with normal liver function and co-infected with chronic HBV and human immunodeficiency virus 1 (HIV-1).Virol J. 2013 Jul 12;10:232. doi: 10.1186/1743-422X-10-232. Virol J. 2013. PMID: 23849342 Free PMC article.
-
Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.J Virol. 2003 Dec;77(24):13248-56. doi: 10.1128/jvi.77.24.13248-13256.2003. J Virol. 2003. Retraction in: J Virol. 2005 Mar;79(5):3229. doi: 10.1128/JVI.79.5.3229.2005. PMID: 14645581 Free PMC article. Retracted.
-
Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer.J Virol. 2000 Sep;74(18):8751-6. doi: 10.1128/jvi.74.18.8751-8756.2000. J Virol. 2000. PMID: 10954578 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials